Zacks Investment Research downgraded shares of IntelGenx Technologies Corp. (NASDAQ:IGXT) from a buy rating to a hold rating in a research note issued to investors on Tuesday, May 16th.

According to Zacks, “IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company’s research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. “

Shares of IntelGenx Technologies Corp. (NASDAQ:IGXT) remained flat at $0.77 during mid-day trading on Tuesday. 73,620 shares of the stock traded hands. IntelGenx Technologies Corp. has a one year low of $0.45 and a one year high of $1.00. The stock’s 50 day moving average price is $0.73 and its 200 day moving average price is $0.77. The company’s market capitalization is $50.37 million.

COPYRIGHT VIOLATION WARNING: “IntelGenx Technologies Corp. (IGXT) Lowered to “Hold” at Zacks Investment Research” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at

Get a free copy of the Zacks research report on IntelGenx Technologies Corp. (IGXT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for IntelGenx Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies Corp. and related stocks with our FREE daily email newsletter.